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Abstract 
Agonists acting on µ-opioid receptors (MOR) are very effective analgesics but cause 
tolerance during long-term or repeated exposure. Intensive efforts have been made to find 
novel opioid agonists that are efficacious analgesics but can elude the signaling events 
that cause tolerance. µ-Opioid agonists differentially couple to downstream signaling 
mechanisms.  Some agonists, such as enkephalins, D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-
enkephalin (DAMGO), methadone and sufentanyl are efficacious at mediating G-protein 
and effector coupling, as well as triggering MOR regulatory events that include MOR 
phosphorylation, ß-arrestin binding, receptor endocytosis and recycling. By contrast, 
morphine and closely related alkaloids can mediate efficacious MOR-effector coupling 
but poorly trigger receptor regulation.  Several models have been proposed to relate 
differential MOR regulation by different opioids with their propensity to cause tolerance.  
Most are based on dogma that ß-arrestin-2 (βarr-2) binding causes MOR desensitisation 
and/or that MOR endocytosis and recycling are required for receptor resensitization.  
This review will examine some of these notions in light of recent evidence establishing 
that MOR dephosphorylation and resensitization do not require endocytosis. Recent 
evidence from opioid treated animals also suggests that impaired MOR-effector coupling 
is driven, at least in part, by enhanced desensitization, as well as impaired resensitization 
that appears to be βarr-2 dependent. Better understanding of how chronic exposure to 
opioids alters receptor regulatory mechanisms may facilitate the development of effective 
analgesics that produce limited tolerance.  
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Introduction 
 
Opioids are potent and effective analgesics. It is well established that nearly all clinically 
used opioids mediate their analgesic effects by activating the µ-opioid receptor (MOR;  
Kieffer and Gaveriaux-Ruff, 2002). However, long-term use of µ-opioid agonists 
produces adverse effects that include the development of tolerance and addiction, limiting 
their clinical utility (Williams et al., 2001; Christie, 2008; Morgan and Christie, 2011).  
Qualitatively, all MOR agonists produce tolerance in vivo although there are differences 
in the extent of tolerance (Morgan & Christie, 2011) suggesting that opioid analgesics 
resistant to tolerance could be developed. Recent promising approaches to limit tolerance 
have been extensively reviewed and include simultaneous activation of more than one 
opioid receptor type (e.g., MOR and DOR-receptors), selective targeting of 
heteromultimers, or opioids that differentially activate distinct intracellular signaling 
cascades, possibly involving differential activation of Gα subtypes (Pineyro & Archer-
Lahlou, 2007), and particularly differential G-protein activation versus endocytosis 
(eg.Martini & Whistler, 2007; Christie, 2008; Koch & Hollt, 2008; Berger & Whistler, 
2010; von Zastrow, 2010). 
 
  The molecular mechanisms mediating opioid tolerance in vivo remain uncertain 
but there is accumulating evidence linking mechanisms of MOR desensitisation- receptor 
phosphorylation, arrestin association, endocytosis, and recycling to tolerance 
development. For example, knockout (k.o.) mice lacking key MOR regulatory proteins, 
including β-arrestin-2 k.o. (βarr-2; Bohn et al., 2000; 2002) exhibited enhanced morphine 
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analgesic responses while development of morphine analgesic tolerance was attenuated.  
Impetus to investigate MOR regulatory mechanisms of tolerance also came from the 
finding that different agonists can differentially engage these mechanisms (Keith et al. 
1996; Whistler & von Zastrow, 1998; Alvarez et al., 2002). There are many reviews on 
the topic (see von Zastrow et al., 2003; Connor et al., 2004; Martini & Whistler, 2007; 
Koch & Hollt, 2008; Berger & Whistler, 2010; von Zastrow, 2010). Notably, morphine 
and closely related alkaloid agonists were found to quite efficaciously activate G-protein 
signaling but poorly mediate endocytosis, whereas most efficacious peptides and some 
small molecule agonists efficiently engage both processes.  
 
The process of MOR regulation is thought to resemble that of the well 
characterized ß2-adrenoceptor.  Briefly, G-protein receptor kinase-2 (GRK2) 
phosphorylation of the agonist bound β2-adrenoceptor enhances its affinity for βarr-2 
binding, triggering receptor endocytosis via clathrin-dynamin dependent mechanisms 
(Gainetdinov et al., 2004). MOR is also predominantly phosphorylated by GRK2 (Wang, 
2000; Li and Wang, 2001), GRK3 and perhaps weakly by GRK5 (Kovoor et al., 1998; 
Terman et al., 2004). To the extent that they have been studied, other GRK isoforms do 
not contribute to acute MOR desensitization (Johnson et al., 2006a). Like the β2-
adrenoceptor, MOR interacts predominantly with βarr-2 (Cheng et al., 1998) although it 
has been suggested that MOR can interact with βarr-1 in the absence of βarr-2 (but not 
with morphine activation: Bohn et al., 2004).  Following endocytosis, MOR is sorted for 
recycling back to the surface membrane (von Zastrow et al., 2003).  Like the ß2-
adrenoceptor, βarr-2-dependent endocytosis and recycling is thought to be essential for 
5 
 
MOR resensitization (Law et al., 2000; Koch et al., 2005) although more recent evidence 
strongly challenges this assumption (Arttamangkul et al., 2006; Dang et al., 2011; Doll et 
al., 2011).   
 
Currently, there are varying and apparently incompatible hypotheses for the 
involvement of MOR regulatory processes in opioid tolerance (see Bohn et al., 2004; 
Koch & Hollt, 2008; Berger & Whistler, 2010). It is widely thought that opioid agonists 
that differentially engage MOR-signaling and receptor regulatory processes have 
different propensity to cause tolerance.   Supporting evidence for this notion revolves 
around the accepted dogma that MOR endocytosis and recycling is required for receptor 
dephosphorylation and resensitization.  This review considers some of these assumptions 
and focuses on how the process of MOR regulation contributes to the development opioid 
tolerance at the receptor level in light of recent findings that strongly suggest that MOR 
desensitization does not require receptor endocytosis and recycling but tolerance does 
involve MOR desensitization, as well as resensitization mechanisms that are arrestin-
dependent. 
 
Definitions of tolerance and desensitization 
 
The terms tolerance and desensitization are often used to describe very different 
processes that may be mediated by distinct mechanisms. Drug tolerance is defined as a 
loss of responsiveness to an agonist after continued exposure and is best quantified by the 
rightward shift in the dose-response curve that may be associated with a reduction in the 
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maximum response in whole animals or similar shifts to concentration-response curves in 
isolated systems. However, common use of the term in different experimental contexts 
can be confusing because the mechanisms regulating MOR function during short-term 
agonist exposure may differ from that during or after long-term agonist exposure. Whilst 
most studies examine tolerance following long-term drug exposure of days to weeks, 
others ascribe tolerance to a very short-term loss of MOR responsiveness that occurs in 
the minutes to several hours after acute agonist exposure either in vivo or in vitro. 
Although the latter is correct usage, it can be confusing because loss of MOR 
responsiveness during short-term, sustained exposure is closely linked to mechanisms of 
rapid MOR desensitization that may include receptor endocytosis rather than long-term 
regulation of MOR function.  As discussed in detail below, the process of rapid MOR 
desensitization certainly contributes to long-term MOR regulation and tolerance but the 
two are not equivalent. As such we restrict the usage of the term “tolerance” to 
phenomena observed after long-term exposure (several days to weeks) to opioids and 
describe short-term studies, where relevant, as “acute-tolerance”.  
 
 
Usage of the term “desensitization” can also be confusing because it is, like 
tolerance, an operational definition for loss of receptor function that can be applied to 
very different phenomena.  Here we adopt the most common usage ascribed to the rapid 
loss of MOR-effector coupling that occurs during sustained exposure to agonists, usually 
in vitro, that occurs within seconds to several minutes. The same term, however, has been 
applied correctly to measurements of MOR-effector coupling in vitro after long-term 
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opioid exposure (eg. Bohn et al., 2000, 2002) which does not actually measure the loss of 
receptor function during sustained agonist application. Loss of sensitivity or what has 
been described as “desensitization” in this context is equivalent to tolerance at the 
cellular or molecular level.  We avoid use of the term “desensitization” in this context 
because it confounds the distinction between loss of MOR function that occurs within 
seconds to minutes during agonist application (usually defined as desensitization) and the 
tolerance (as defined above) that develops over days and weeks.   
 
As introduced above, the process of MOR regulation involves multiple processes, 
including phosphorylation, arrestin binding, endocytosis, and resensitization (de-
phosphorylation); which may not require receptor endocytosis and recycling.  It is 
therefore important to note that measurements of MOR desensitization as defined here 
can encompass multiple components of the MOR regulatory processes, depending on the 
temporal resolution of the assay. Thus measurements of desensitization may include loss 
of MOR-effector coupling prior to endocytosis (seconds to several minutes), 
desensitization due to endocytosis (which produces loss of MOR-effector coupling by 
removing receptors from the surface membrane; usually 2-30 min) or resensitization and 
recycling (which slowly reverses desensitization; usually 20 min-1h). Assays of MOR 
activation of G-proteins employing methods such as activity of G-protein-modulated ion 
channels (e.g. Dang et al., 2009) or resonance energy transfer (RET) methods (e.g. 
Molinari et al., 2010) continuously monitor MOR signaling over time scales of seconds 
to minutes during and shortly after induction of desensitization, so can easily distinguish 
these components. However, biochemical assays for desensitization, such as inhibition of 
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adenylate cyclase, that require more than 5 min of sustained opioid exposure (most assays 
take 10-20 min, eg. Law et al., 2000, or longer, e.g. Koch et al., 2005) may be measuring 
the combined effects of rapid desensitization at the cell surface plus endocytosis or 
resensitization (Connor et al., 2004). Therefore, attempts to compare kinetics and 
mechanisms regulating MOR signaling across studies can be confusing.  Careful 
consideration should be given to the duration of agonist treatment and the time required 
to measure MOR-effector coupling when comparing mechanisms of MOR regulation 
across assays because multiple components may be involved.  
 
Differential MOR desensitization, endocytosis and tolerance 
 
Differential agonist efficacy for G-protein signaling and endocytosis 
The discovery that different opioid agonists have different efficacies for G-protein 
signalling and mediation of receptor endocytosis has provided impetus to determine 
whether MOR regulatory mechanisms contribute to tolerance, which could explain why 
MOR function is lost in the absence of reduced MOR expression.  It has been 
hypothesized that the inability of morphine to initiate efficient MOR endocytosis gives 
morphine high liability for causing tolerance.  Many studies have established that 
morphine activates MOR but poorly induces endocytosis (Arden et al., 1995; Keith et al., 
1996; Sternini et al., 1996; Whistler & von Zastrow, 1998; Borgland et al., 2003), as 
widely reviewed (see von Zastrow et al., 2003; Connor et al., 2004; Martini & Whistler, 
2007; Koch & Hollt, 2008; Berger & Whistler, 2010; von Zastrow, 2010). Most 
quantitative studies of signaling efficacy have concluded that intrinsic efficacy to activate 
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G-proteins versus endocytosis or βarr-2 association with MOR are not linearly related 
(Borgland et al., 2003; Molinari et al., 2010; but also see McPherson et al., 2010).  
Molinari et al. (2010) using RET methods, reported a hyperbolic relationship between 
intrinsic activity for G-protein and βarr-2, consistent with earlier studies. By contrast, 
McPherson et al., (2010) found a more linear relationship for both βarr-2 recruitment and 
endocytosis, with some outliers (but not morphine). This discrepancy could be due to the 
methods used to determine G-protein activation (GTPS binding for 2 h by McPherson et 
al., 2010 and RET methods by Molinari et al., 2010), the expression of different densities 
of RET donors and acceptors in the two studies or the use an operational model for 
analysis by McPherson et al. (2010) but not Molinari et al. (2010). It is well established 
that overexpression of GRKs or arrestins can profoundly enhance induction of 
endocytosis by morphine (eg. Whistler & von Zastrow, 1998; Bohn et al., 2004).  
Morphine also fails to induce MOR endocytosis in spinal cord in vivo (Trafton et al., 
2002) but it efficiently induces endocytosis in medium spiny striatal neurons, 
(Haberstock-Debic et al., 2003; Yu et al., 2010). 
 
Do strongly- internalizing opioid agonists produce less tolerance than weakly-
internalizing agonists? 
Morphine produces more behavioural tolerance than strongly internalizing agonists. This 
finding has been widely cited to support the notion that MOR recycling influences 
tolerance. Morphine, for instance, produced greater opioid tolerance when compared to 
agonists like DAMGO, sufentanyl or etorphine, when equivalent induction doses and 
continuous infusions were used to control for pharmacokinetic differences (Stevens & 
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Yaksh 1989; Duttaroy & Yoburn, 1995; Madia et al., 2009).  Whilst this seems to support 
the notion that strongly-internalizing agonists produce less tolerance than weakly-
internalizing agonists, the interpretation is seriously confounded by large differences in 
intrinsic efficacy for G-protein activation among these agonists. Etorphine, sufentanyl 
and DAMGO all exhibit much higher intrinsic efficacy for G-protein activation than 
morphine (Traynor & Nahorski, 1995; Emmerson et al., 1996; Selley et al., 1998; 
McPherson et al., 2010; Molinari et al., 2010) although some studies using GTPS 
binding have reported that the intrinsic efficacy of sufentanyl is comparable to morphine 
(Emerson et al., 1996; Selley et al., 1998). Low intrinsic efficacy agonists usually 
produce larger rightward shifts in concentration-response curves than high efficacy 
agonists. This occurs when MOR-effector coupling is impaired either by irreversible 
antagonists or chronic drug treatment presumably because low intrinsic efficacy agonists 
such as morphine must occupy a greater fraction of the total receptor population to 
produce a given level of effect, due to lesser receptor reserve (eg. Christie et al., 1987; 
Stevens & Yaksh, 1989; Mjanger & Yaksh, 1991; Connor et al., 1999).   
 
 To properly test the notion that strongly- versus weakly-internalizing opioids 
produce differential tolerance would therefore require direct comparison of the extent of 
tolerance produced by morphine with opioids that exhibit comparable intrinsic efficacy 
for G-protein activation but much higher efficacy for endocytosis than morphine, while 
ensuring equivalent receptor stimulation and duration of action. Methadone and 
endomorphins  have been considered good candidates because their intrinsic efficacies 
for G-protein activation appear similar to morphine and both efficiently induce MOR 
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endocytosis. However, the intrinsic efficacy of methadone is more similar to DAMGO 
than morphine in GTPS assays (Selley et al., 1998; McPherson et al., 2010) and in vivo 
(Adams et al., 1990). The apparently low efficacy of methadone in electrophysiological 
studies is caused by non-MOR actions on ion channels (Rodriguez-Martin et al., 2008).  
Methadone and endomorphins also have very different pharmacokinetic properties and 
toxicity compared to morphine that can further complicate interpretations.  Although He 
& Whistler (2005) did examine this issue using methadone and morphine, the results are 
very difficult to interpret because i.c.v. dose-equivalence was not established. By 
contrast, Soignier et al. (2004) reported comparable rates of tolerance development and 
completely symmetrical cross-tolerance during continuous i.c.v. infusion of morphine, 
endomorphin-1 and endomorphin-2, suggesting tolerance may not be different between 
strongly and weakly-internalizing agonists when intrinsic efficacy is matched. 
Furthermore, there is no clear evidence that strongly-internalizing agonists produce 
differential tolerance compared with weakly-internalizing opioids in humans (Morgan & 
Christie, 2011). For example, comparison of tolerance development in pain patients 
during continuous administration of transdermal fentanyl (high efficacy, moderate 
endocytosis) versus buprenorphine (low efficacy, non-internalizing) found fentanyl 
produced greater tolerance (Sittl et al., 2006).  Therefore, it remains uncertain whether or 
not strongly-internalizing agonists produce less tolerance than weakly-internalizing 
agonists. 
 
Decreased MOR-effector coupling contributes to opioid tolerance 
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Chronic exposure to opioids can cause profound tolerance in both animals and humans 
(Christie, 2008; Morgan and Christie, 2011).Tolerance measured in whole animals is 
mediated by multiple adaptive mechanisms ranging from molecular mechanisms of 
MOR-effector coupling in neurons, second messenger systems in opioid sensitive cells, 
non-neuronal cells (including glia) and neural networks interacting with opioid sensitive 
neurons, to learned behaviour in animals (see Christie, 2008).  Nonetheless, there is very 
solid evidence that impaired MOR-effector coupling contributes to tolerance in vivo.  
 
Opioid tolerance has been extensively quantified in isolated tissues, neurons and 
membrane preparations from morphine tolerant animals, as well as in cell culture models. 
Functional measurements of impaired MOR-effector coupling in isolated tissues and cells 
after chronic morphine treatment consistently show a loss of functional receptors without 
consistent changes in MOR binding density (down-regulation, reviewed by Koch & 
Hollt, 2008; Christie, 2008). Agonists that strongly promote MOR endocytosis, such as 
etorphine, are an exception because they do induce receptor down-regulation (Stafford et 
al., 2001), presumably because a small proportion of endocytosed MOR is degraded 
during each internalization cycle (Whistler et al., 2002).  
 
Operational models (or Fuchgott analysis) used to quantify the loss of functional 
MOR-effector coupling in isolated systems (eg. Chavkin & Goldstein, 1984; Christie et 
al., 1987;  Bailey et al., 2009a) after chronic morphine have calculated a loss of 
approximately 80% of functional surface MOR is required to account for the observed 
shift in agonist concentration-response curves.  Studies using physiological end-points 
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(direct Gβ interactions with ion channels) in single opioid sensitive neurons have 
reported impaired MOR-effector coupling in a range of neuronal cell types from animals 
that have been chronically treated with morphine in vivo (except Ingram et al., 2008), 
including rat and mouse periaqueductal grey (PAG, Bagley et al., 2005), rat and mouse 
locus coeruleus (LC, Christie et al., 1987;  Connor et al., 1999; Dang & Williams, 2004; 
Bailey et al., 2009a; Dang et al., 2011; Quillinan et al., 2011) and mouse trigeminal 
ganglion neurons (Johnson et al., 2006b). Similar results were also reported for inhibition 
of GABAergic synaptic transmission in nerve terminals in PAG (Fyfe et al., 2010; Hack 
et al., 2003). These findings are consistent with those examining MOR-activated GTPS 
binding in brainstem in parallel with MOR binding density (Bohn et al., 2000) and 
GTPS binding in some brain regions but not others (Sim et al., 1996; Kim at al., 2008). 
Taken together, these results are consistent with earlier reports in cultured cells showing 
that chronic morphine exposure impaired MOR-effector coupling (GTPS binding) 
without greatly affecting MOR binding density (Puttfarcken et al., 1988; Puttfarcken & 
Cox, 1989). 
 
β-Arrestin-2 and endocytic mechanisms are involved in opioid tolerance 
Although the phenomenon that chronic morphine impairs MOR-effector coupling 
without much effect on MOR binding density has been known for more than 20 years, the 
mechanisms responsible are still uncertain and controversial.  There is, however, 
accumulating evidence that the MOR regulatory mechanisms involved in acute 
desensitization, including association with βarr-2 and endocytosis, are intimately 
involved in the development of opioid tolerance.  
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Bohn et al. (2000, 2002, 2004) established that development of morphine antinociceptive 
tolerance (but not withdrawal) is blunted in βarr-2 k.o. mice. Concurrently, GTPS assays 
in brainstem membranes from the k.o. mice also showed a blunted shift in the 
concentration response curve (tolerance).  Acute antinociceptive responses to morphine 
(but not etorphine, fentanyl or methadone; Bohn et al., 2004; or other opioid actions of 
morphine, Raehal et al, 2005) were also enhanced in the βarr-2 k.o.  It was suggested that 
MOR is resistant to desensitization in the absence of βarr-2 (see contrary evidence; 
Bradaia et al., 2005; Walwyn et al., 2007; Dang et al., 2009; Dang et al 2011).  
Additional support for the involvement of MOR regulatory processes in the development 
of opioid tolerance comes from study using GRK3 k.o. mice.  This study showed MOR 
tolerance was reduced in hippocampal neurons from GRK3 k.o. mice (Terman et al., 
2004). Development of behavioural tolerance to fentanyl was attenuated, however, there 
was no effect on morphine tolerance.  Together, these studies firmly establish that 
arrestin-dependent MOR regulation is linked to morphine tolerance.  
 
These studies suggest that blocking MOR endocytosis, which is presumably 
impaired in the βarr-2 k.o. (but see Arttamangkul et al., 2008; Quillinan et al., 2011) 
attenuates tolerance but others have provided seemingly contradictory evidence that 
induction of MOR endocytosis and recycling limits morphine tolerance and suppression 
of endocytosis or recycling enhances it. He et al. (2002) reported that inclusion of an 
extremely low dose of a strongly-internalizing agonist, DAMGO (that had no 
antinocicpetive effect on its own), with constantly infused i.t. morphine limited the 
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development of tolerance and also stimulated MOR endocytosis in spinal cord and 
cultured cells (but see contrary evidence, Bailey et al., 2003; Koch et al., 2005). This was 
not observed with either drug alone at the doses used. The authors hypothesized that a 
very low concentration of DAMGO, which does not induce detectable endocytosis by 
itself, can stimulate endocytosis of morphine occupied MOR and thereby reduces 
tolerance, perhaps via interaction with homomultimers of MOR. Similarly, Kim et al. 
(2008) studied a transgenic MOR mouse, in which part of the C-terminal region of the 
DOR is substituted into MOR (rMOR). This conferred the ability of morphine to 
efficiently mediate MOR endocytosis and recycling. The rMOR mice showed similar 
antinociceptive sensitivity to morphine as wild-types but developed less morphine 
antinociceptive tolerance, as well as less reduction in MOR-activated GTPS binding in 
brainstem membranes. Consistent with these studies, the converse has also been reported 
in spinophilin k.o. mice (Charlton et al., 2008); development of morphine tolerance was 
enhanced in spinophilin k.o. mice. Spinophilin is a neuronal scaffolding protein that 
facilitates MOR endocytosis, so endocytosis should be impaired in the k.o., although 
other regulatory actions of spinophilin cannot be ruled out. Taken together, these studies 
suggest that MOR endocytosis limits tolerance and, therefore, opioids that do not 
promote receptor endocytosis should produce greater tolerance than agonists that do 
promote MOR endocytosis (but see above for lack of direct behavioral evidence that this 
is the case). 
 
The findings described above appear contradictory in terms of the relationship 
between endocytosis and tolerance. On the one hand, blocking βarr-2 association with 
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MOR (which should impair endocytosis) inhibits morphine tolerance and, on the other, 
manipulations that enhance MOR endocytosis (and vice versa) impair development of 
morphine tolerance.  Various explanations have been proposed to account for these 
disparate findings. In the case of manipulations that prevent βarr-2 binding, it was 
proposed that βarr-2 association is necessary for, or facilitates MOR desensitization 
(Bohn et al., 2002; 2004, but see below). However, desensitization (as defined above) 
was not directly examined in those studies. But examination of MOR desensitization in 
both sensory and LC neurons show that it is unaffected by βarr2- deletion.  It is therefore 
unclear how βarr-2 deletion can account for blunted tolerance in the k.o. mice.  Two 
general interpretations (not mutually exclusive) for the inhibition of tolerance were 
developed by Whistler and co-workers that are in line with findings from other groups 
(eg. Berger & Whistler, 2010). One interpretation is that strongly internalizing agonists 
produce less tolerance because the cycles of endocytosis promote dephosphorylation of 
MOR in endososmes and resensitized receptors are then recycled to the cell surface.  
Because morphine poorly stimulates endocytosis of phosphorylated and desensitized 
MOR (whether or not MOR associated with arrestins) the desensitized receptors 
accumulate at the cell surface causing tolerance. The other interpretation is that morphine 
causes persistent signaling that contributes to secondary adaptations involved in tolerance 
in vivo, whereas endocytosis terminates persistent signalling, limiting downstream 
adaptations and tolerance. These concepts are summarized in Figure 1. These authors 
have also provided extensive evidence that such secondary adaptations are more 
pronounced following chronic morphine stimulation of wild type MOR compared to 
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chimeric MOR that can undergoes endocytosis and recycling when stimulated by 
morphine (ibid.).  
 
In essence both types of study described above include the notion that arrestin-
dependent endocytosis and recycling is necessary for MOR resensitization to occur. This 
notion is based largely on the model established for β2-adrenoceptor recycling 
(Gainetdinov et al., 2004).  Although some studies appear to support this for MOR (Koch 
et al., 1998; Law et al., 2000; Koch et al., 2001; Qui et al., 2003), more recent findings 
discussed below clearly establish that MOR dephosphorylation proceeds efficiently at the 
cell surface, as does resensitization in the βarr-2 k.o. or when endocytosis is blocked.   
 
MOR desensitization does not require βarrestin and is distinct from endocytosis 
 
Two lines of evidence directly establish that MOR desensitization does not require 
endocytosis. Arttamangkul et al. (2006) directly studied desensitization and endocytosis 
of MOR in cultured LC neurons in parallel with a transgenic FLAG-tagged MOR mouse. 
The lectin,  concanavalin-A, completely blocked endocytosis induced by met-enkephalin 
but did not affect desensitization. Similarly, Dang et al. (2009) reported that inhibition of 
dynamin-dependent endocytosis had no effect on the rate or extent of MOR 
desensitization induced by met-enkephalin in mouse LC neurons. Whilst endocytosis 
could produce desensitization by removing MOR from the surface membrane, it is clear 
from these studies that functional desensitization of MOR-effector coupling does not 
require it. 
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Kinetics of desensitization and endocytosis   
MOR desensitization and endocytosis can also be distinguished on the basis of time 
course and differential efficacies of opioid agonists.  Kinetically, rapid desensitization of 
MOR largely precedes endocytosis for high efficacy peptide agonists. The time constants 
for rapid desensitization in neurons and cultured cells are of the order of 1-3 min at 33-
37o (Bailey et al., 2004; Dang & Williams, 2004; Arttamangkul et al., 2006; Dang et al., 
2009), when measured during stimulation by high efficacy, strongly-internalizing 
agonists (eg. met-enkephalin, DAMGO) and other methods that provide reliable data in 
the second to minute range (Connor et al., 2004), after which the process reaches steady 
state in less than 10 min. The time course of MOR desensitization is also similar to that 
reported for βarr-2 association (Oakley et al., 2000; McPherson et al., 2010; Molinari et 
al., 2010) and phosphorylation of  residues in the C-terminal region of MOR (T370 and 
S375; Doll et al., 2011), all of which saturated within 2-3 min when stimulated by 
efficacious peptide agonists.  Endocytosis induced by the same agonists is somewhat 
slower, with time constants generally in the order of > 5 min and reaching steady state in 
less than 30 min (Law et al., 2000; Borgland et al., 2003; Tanowitz & von Zastrow, 
2003; Johnson et al., 2006a; Arttamangkul et al., 2006, 2008; Tanowitz et al., 2008). This 
suggests that MOR desensitization and endocytosis may occur as separate or sequential 
processes with some temporal overlap.   
 
Differential efficacy of opioids for desensitization and endocytosis 
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In some studies (but not others) opioids differentially couple to desensitization and 
endocytosis. In heterologous expression systems a range of opioid agonists, including 
morphine, can cause desensitization (Borgland e al., 2003; Johnson, 2006a; Chu et al., 
2010). Intrinsic efficacies of several opioids to cause G-protein activation is highly 
correlated with their efficacy to produce rapid desensitization. It should be noted that 
much higher levels of receptor occupancy are required for the latter, ie. the coupling  
efficacy is approximately 10-fold lower for desensitization than G-protein activation 
(Borgland et al., 2003).  However, this was not the case for endocytosis when the same 
agonists are used; morphine displayed distinctly lower efficacy than expected from either 
G-protein activation or desensitization.  Earlier studies that claimed a strong correlation 
between the intrinsic efficacy for desensitization and endocytosis in cultured cells (Koch 
et al., 2005) could have been confounded because the duration of the desensitization 
assays used (inhibition of cAMP formation) encompassed both phenomena.   
 
By contrast with cultured cells, morphine produces little desensitization in native LC 
neurons (Dang & Williams, 2005; Virk & Williams, 2008; Bailey et al., 2009b). In these 
cases, desensitization appears better correlated with capacity to induce MOR endocytosis 
than G-protein activation.   Bailey and co-workers have provided a potential explanation 
for the differences between some cultured cells and this has been confirmed by others 
(Chu et al., 2010).  In cultured cells (HEK293), morphine- but not DAMGO-induced 
desensitization is blocked by protein kinase C (PKC) inhibition (Johnson et al., 2006a). 
Conversely, in LC neurons, where morphine induces little desensitization, PKC 
activation enhances morphine-induced (but not DAMGO) desensitization (Bailey et al., 
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2009b). This provides clear evidence of agonist-dependent differential desensitization, 
with morphine but not DAMGO being PKC-dependent. The same studies suggested the 
reverse sensitivity for GRK inhibition, with DAMGO-induced desensitization being more 
sensitive to disruption of GRK than morphine (but see lack of effect of GRK inhibition 
alone in Dang et al., 2009). 
 
Differential MOR phosphoryaltion and desensitization 
Opioid agonists can differentially phosphorylate MOR (Johnson et al 2006a).  This could 
provide a plausible explanation for differential desensitization between morphine and 
DAMGO and its dependence on PKC phosphorylation in some cell types. Serial 
phosphorylation of up to 20 potential sites in the intracellular regions of MOR contribute 
to receptor desensitization and endocytosis , particularly GRK substrates near the C-
terminal (see Koch & Hollt, 2008; Connor et al., 2004 for review). Some of these sites 
are essential for GRK phosphorylation and arrestin-dependent endocytosis (ibid.).  
Mutation of several residues in the C-terminal of MOR (S363, T370 or S375 to A) 
impairs DAMGO mediated receptor phosphorylation and endocytosis (El Kouhen et al., 
2001; Schulz et al., 2004).  Until recently, only S375 has been shown to undergo agonist 
specific phosphorylation by both DAMGO and (more slowly) morphine using 
phosphosite specific antibodies (Schulz et al., 2004).   
 
More recently, Doll et al. (2011) have produced phosphosite specific antibodies 
for S363, T370 and S375 of mouse MOR. They showed that S363 was constitutively 
phosphorylated in HEK293 cells. They confirmed that both DAMGO and morphine (less 
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efficiently) induced phosphorylation of S375. DAMGO also induced efficient 
phosphorylation of T370 but morphine did not. Importantly, PKC stimulation directly 
phosphorylated at T370 in an agonist-independent manner.  This appears to provide a 
nice explanation of the PKC dependence of morphine- but not DAMGO-induced 
desensitization. If efficient desensitization requires phosphorylation of bothT370 and 
S375 then morphine-induced desensitization would require PKC activation but DAMGO 
would not. PKC activation might therefore be sufficient to induce desensitization when 
S375 (and perhaps other unidentified sites) is also phosphorylated. It is conceivable that 
in addition to phosphorylation of both T370 and S375, additional phosphorylation events 
are required to facilitate βarr-2 binding, so phosphorylation of  T370 and S375 may be 
necessary (El Kouhen et al., 2001) but not be sufficient to induce effective βarr-2-
dependent endocytosis when morphine is the agonist.  
 
βarr-2 is not necessary for desensitization of MOR  
A possible interpretation of the effects of the βarr-2 k.o. on development of morphine 
tolerance is that βarr-2 association with MOR is necessary for desensitization (see 
above).  Although this may be correct for some neurons, it is clearly not the case in 
neurons studied to date, or HEK293 cells where morphine efficiently induces 
desensitization but not βarr-2-dependent endocytosis . Walwyn et al. (2007) showed that 
DAMGO-induced desensitization of MOR coupling (Gβ mediated) to voltage gated 
calcium current inhibition in sensory neurons was unaffected in the βarr-2 k.o. and this 
was substantiated by (Arttamangkul et al., 2008) in LC neurons. More recent studies 
established in LC that desensitization induced by met-enkephalin can be mediated by at 
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least two distinct mechanisms independently involving ERK1/2 activity and GRK2-βarr-
2 (Dang et al., 2009). Blocking either mechanism alone was not sufficient to inhibit 
desensitization.  The specific process for the ERK1/2-dependent mechanism is not yet 
known but MOR desensitization, internalization and phosphorylation have all been 
reported to be prevented by ERK1/2 inhibition in some heterologous expression systems 
(Polakiewicz  et al., 1998; Schmidt et al., 2000).  As is likely for the initial events of the 
GRK-βarr-2 interaction, signalling by ERK1/2 may therefore prevent coupling of MOR 
to effectors by phosphorylating MOR at sites not occupied by Gα-subunits (Schmidt et 
al., 2000). Alternatively, ERK1/2 may act indirectly to mediate desensitization via 
phosphorylation of Gα-interacting protein (GAIP), a regulator of G-protein signalling 
(RGS) by potentiating the rate of GTP hydrolysis, as has been reported in some cell types 
(Ogier-Denis et al., 2000).  There are many other possible mechanisms involved in MOR 
desensitization and endocytosis that could be differentially affected by morphine-like 
opioids (Koch & Hollt, 2008), including facilitating translocation of MOR from lipid raft 
domains (Zheng et al. 2008) or activation of phospholipase D2 (Koch et al., 2006), both 
of which are poorly induced by morphine.  Acute tolerance to morphine in vivo is also 
differentially sensitive to inhibition of c-Jun N-terminal kinase compared with strongly-
internalizing agonists such as fentanyl (Melief et al., 2010). 
 
These findings also underscore the possibility that desensitization may be 
mediated by multiple mechanisms in different cell types or cellular compartments. LC 
neurons display strong ERK1/2 activation (Eitan et al., 2003; Dang et al., 2009) after 
opioid administration but many other neurons (and cell types) do not (Eitan et al., 2003). 
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Therefore, desensitization may be mediated primarily by GRK- βarr2-dependent 
mechanisms in some neuronal types (eg. Li & Wang, 2001) but can be initiated by other 
redundant mechanisms in other cells (see Koch & Hollt, 2008).  Other differences 
between cell types can influence MOR desensitization, e.g., the capacity of opioids to 
induce endocytosis can be strongly influenced by co-expression of other GPCRs such the 
NK1 receptor in the same cell (Yu et al., 2009). It is also likely that the mechanisms of 
desensitization are distinct in different cellular compartments.  Fyfe et al. (2010) reported 
that no desensitization of MOR-induced presynaptic GABAergic inhibition, during 
superfusion of morphine, met-enkephalin or DAMGO for up to 30 min in rat PAG 
neurons; even when a fraction of receptors had been inactivated with an irreversible 
MOR antagonist to rule out the potential confound of large receptor reserve.  
 
Morphine tolerance is associated with enhanced MOR desensitization 
Desensitization induced by met-enkephalin, DAMGO and morphine (and methadone, 
Quillinan et al., 2011) are all more pronounced in LC (Dang & Williams, 2004; 2005), as 
well as PAG neurons (Ingram et al., 2008) after chronic exposure to morphine.  
Enhanced desensitization would be expected to contribute to opioid tolerance by more 
prominently reducing functional MOR on cell surface during episodes of agonist 
administration.  There are many possible adaptations caused by chronic morphine that 
could be responsible for this observation but enhanced endocytosis does not appear to be 
responsible.  Enhanced desensitization after chronic morphine treatment was associated 
with reduced endocytosis (Quillinan et al., 2011). Other adaptive mechanisms could 
include those directly involved with MOR phosphorylation such as ERK1/2, GRKs (but 
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GRK2 is decreased; Fan et al., 2002) or arrestins (but βarr-2 is decreased in PAG; Fan et 
al., 2003) or others such as RGS proteins (Gold et al., 2003), phospholipase D2 (Koch et 
al., 2006) or spinophilin (Charlton et al., 2008).   
 
Resensitization and dephosphorylation of MOR do not require endocytosis and 
recycling 
 
The models of differential tolerance between strongly- and weakly-internalizing agonists 
introduced above generally require endocytosis and recycling to resensitize MOR. 
Morphine and similar agonists, by failing to induce endocytosis, are thought to produce 
accumulation of desensitized MOR at the cell surface, thereby producing tolerance.  
More recent evidence discussed below establishes that MOR dephosphorylates and 
resensitizes efficiently at the cell surface regardless of whether strongly- or weakly-
internalizing agonists are examined, so other explanations for the involvement of MOR 
regulatory mechanisms in tolerance are required. 
 
Schulz et al. (2004) provided evidence that recycling may be required to 
dephosphorylate MOR at S375. Briefly, phosphorylation  of  S375 persisted long after 
removal of morphine from cells but was readily reversible using the strongly-
internalizing agonist, DAMGO (but see below for strong evidence to the contrary). 
Functional studies using inhibition of cAMP formation as an endpoint showed monensin 
(to inhibit endosomal recycling), truncated MOR mutants (Qiu et al., 2003) or MOR 
splice variants (Koch et al., 2001; Tanowitz & von Zastrow, 2003; Tanowitz et al., 2008) 
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all reduced both recycling and resensitization of endocytosed MOR.  Although these 
appear to support a requirement for endocytosis and recycling to resensitize MOR, assays 
of MOR function were performed over time scales greatly exceeding acute 
desensitization of G-protein coupling to MOR (see above), ßarr-2 binding (Oakley et al., 
2000), endocytosis (Tanowitz and von Zastrow, 2003; Arttamangkul et al., 2006, 2008) 
and often recycling (Koch et al., 2001; Tanowitz & von Zastrow, 2003; Arttamangkul et 
al., 2008; Tanowitz et al., 2008)  Therefore, such methods cannot distinguish recovery of 
functional MOR at the cell surface from the increased MOR surface density (and 
therefore function) resulting from recycling (Connor et al.,2004).  
 
More recent studies have established conclusively that endocytosis is not 
necessary for either resensitization or dephosphorylation of MOR. Using met-enkephalin 
in cultured LC neurons, Arttamangkul et al. (2006) showed directly that concanavalin A 
blocks endocytosis of  FLAG-tagged MOR but does not affect resensitization. Doll et al. 
(2011) have shown conclusively that dephosphorylation of S375 is rapid using both 
DAMGO and morphine as agonists.  This contradicts the earlier study of Schulz et al. 
(2004) but the explanation may be that morphine did not wash effectively from the cell 
preparations in the earlier study because in Doll et al. (2011) dephosphorylation for 
several agonists was enhanced by a brief rinse with low pH which presumably facilitates 
agonist removal from the preparation.  More importantly, Doll et al. (2011) showed that 
after DAMGO exposure, dephosphorylation of both S375 and T370 were just as rapid in 
cells incubated in concanavalin A, which completely blocked endocytosis. Although 
these findings may not generalise to the many other phosphorylation sites on MOR (see 
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Koch & Hollt, 2008) they do establish that sites involved in βarr-2 binding 
dephosphorylate just as efficiently when endocytosis is blocked. 
 
Recent studies of MOR resensitization in LC neurons from βarr-2 k.o. and 
wildtype mice (Dang et al., 2011; Quillinan et al., 2011) are consistent with the study of 
Doll et al. (2011). If arrestin-dependent endocytosis is required for MOR resensitization 
then recovery from desensitization induced by a strongly-internalizing agonist should be 
impaired but the opposite was found. In wild-type mice, MOR resensitized slowly after 
met-enkephalin induced desensitization (approximately 60 min), similar to that reported 
earlier for LC neurons from rat (Osborne &Williams, 1995; Dang & Williams, 2004) and 
similar to the rate of MOR recycling reported in cultured cells (Koch et al., 2001; 
Tanowitz and von Zastrow, 2003).  In LC neurons from βarr-2 k.o. mice MOR 
resensistization was accelerated, being nearly complete within 20 min (Dang et al., 2011; 
Quillinan et al., 2011). Accelerated resensitization in the βarr-2 k.o. was mimicked in 
wildtype LC by manipulations that should block arrestin association upstream (an 
intracellular GRK inhibitor) or endocytosis downstream of arrestin association (an 
intracellular dynamin inhibitor; Dang et al., 2011). Conversely, resensitization was 
slowed by a phosphatase inhibitor under conditions of impaired arrestin association (βarr-
2 k.o. plus GRK inhibitor, Dang et al., 2011). This shows that MOR resensitization is 
rapid when endocytosis is blocked and the time course is quite consistent with the 
dephosphorylation rate reported by Doll et al. (2011). The slow resensitization in 
wildtype LC is almost certainly due to the fact that once receptors are endocytosed, 
relatively slow receptor recycling (Koch et al., 2001; Tanowitz and von Zastrow, 2003) is 
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necessary for recovery of MOR localization and signaling at the surface membrane. It 
should be noted that such resensitization rates may differ in different neurons because the 
three most abundant splice variants recycle at different rates (MOR1, MOR1A and 
MOR1B, Oldfield et al., 2008). 
 
 The necessity for endocytosis and recycling to resensitize some GPCRs 
presumably depends on the affinity of arrestins for the agonist occupied receptor (Oakley 
et al., 1999, 2000; Ganetdinov et al., 2004). The rapid resensitization and 
dephosphorylation of MOR at the cell surface suggests that the affinity of the βarr-2 
association is relatively weak (Oakley et al. , 2000), so that it can dissociate rapidly prior 
to endocytosis thereby exposing the phosphorylated C-terminal residues (S375, T370 and 
presumably others) to phosphatases . The very rapid reversal of MOR-βarr-2 RET signals 
upon agonist washout reported by McPherson et al. (2010) for most strongly- and 
weakly-internalizing opioids (except etorphine, which has extremely high affinity for 
MOR) is consistent with this possibility. 
 
Arrestin-dependent impairment of MOR resensitization contributes to morphine 
tolerance 
 
Impairment of the capacity of MOR to rapidly resensitize appears to contribute to 
morphine tolerance. In addition to enhanced desensitization, MOR resensitization is 
impaired in LC neurons after chronic morphine (Dang & Williams, 2004) but the 
mechanisms are still not certain.  Dang et al. (2011) and Quillinan et al. (2011) recently 
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confirmed this in mouse LC and further established that the impairment is arrestin-
dependent.  Impaired MOR resensitization after chronic morphine in wildtype LC 
neurons was reversed and resembled that in the βarr-2 k.o. either by disrupting GRK2 
function or inhibition of dynamin function with intracellular inhibitors. These findings 
link the impairment of MOR resensitization in LC to adaptations within the process of 
GRK2-βarr-2-dynamin-dependent MOR regulation.   
 
Dang et al. (2011) and Quillinan et al. (2011) also reported that cellular morphine 
tolerance in the same population of LC neurons was similar to that previously reported in 
wildtype neurons (see above) but abolished in the βarr-2 k.o.  The finding that morphine 
treatment failed to produce cellular tolerance in LC neurons from βarr-2 k.o. mice is 
consistent with the seminal findings that analgesic morphine tolerance, as well as 
tolerance to DAMGO stimulated GTPS binding in brainstem and spinal cord 
membranes, is attenuated in these animals (Bohn et al., 2000; Bohn et al., 2002). These 
findings suggest that persistence of rapid recovery from desensitization after chronic 
morphine could contribute to the attenuation of behavioural opioid tolerance in βarr-2 
k.o. mice if the mechanism found in LC is found to generalise to analgesia-related 
neurons.  It was proposed that following chronic morphine, βarr-2-dependent regulation 
of MOR is enhanced, slowing MOR resensitization, thereby shifting the equilibrium 
between receptor desensitization and resensitization to an accumulation of desensitized 
MOR that accounts for MOR tolerance (Dang et al., 2011).  As such, ablation of βarr-2 in 
the k.o. mice facilitates resensitization and prevents cellular opioid tolerance in LC 
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neurons. Impaired resensitization could be important for tolerance in vivo if the 
phenomenon is found to generalize to neurons involved in analgesia. 
 
The mechanisms of enhanced desensitization (see above) and βarr-2-dependent 
impairment of resensitization during chronic morphine treatment in vivo are still not 
known. Impaired resensitization was observed after very brief exposure to met-
enkephalin and was sensitive to GRK, βarr-2 or dynamin inhibition suggesting a possibly 
enhanced rate of GRK phosphorylation after chronic morphine that engages βarr-2 and 
clathrin-dynamin dependent processes (Dang et al., 2011).  Quillinan et al. (2011) also 
reported in a GRK2 transgenic that can be blocked by a novel agent (NaPP1) that both 
impaired resensitization and cellular opioid tolerance in LC neurons were reversed by the 
GRK2 inhibitor. The dependence of both tolerance and resensitization on GRK, βarr-2 
and dynamin would predict the explanation for MOR tolerance (and slow resensitization) 
may be an enhanced rate of endocytosis after chronic morphine.  However, Quillinan et 
al. (2011) found no difference in the extent of met-enkephalin-induced MOR endocytosis 
in LC neurons from chronically treated with morphine. Similarly, the extent of 
endocytosis induced by DAMGO in spinal cord in vivo was also not reduced by chronic 
morphine treatment (Trafton & Basbaum, 2000).  The latter findings seem at odds with 
the effects of βarr-2-deletion and dynamin-inhibition. The mechanism of impaired 
resensitization is, therefore, still unclear but a range of adaptations produced by chronic 
morphine could be responsible. Although untested, it is possible sites other than T370 
and S375 are more persistently phosphorylated by chronic morphine to enhance other 
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downstream events that do not increase endocytosis or that post-endocytic trafficking and 
sorting mechanisms are affected by chronic morphine.  
 
Concluding remarks 
 
The discovery of differential signaling efficacies of opioid agonists for G-protein 
coupling, desensitization and endocytosis and their potential involvement in the 
development of opioid tolerance stimulated much research to understand these 
mechanisms with the hope of developing opioids that can elude or limit tolerance.  This 
idea seems to be substantiated by the consistent findings that greater opioid tolerance 
develops to agonists with low (morphine and related alkaloids) versus high (enkephalin-
related peptides, sufentanyl, etorphine etc) differential efficacy for endocytosis. However, 
that interpretation is much less certain when the direct influence of intrinsic efficacies of 
these drugs for G-protein signaling on tolerance are taken into account.  Nonetheless, the 
effects on morphine tolerance of genetically ablating trafficking proteins (βarr-2 k.o.) or 
constructing MOR mutants that recycle efficiently with morphine both strongly suggest 
MOR desensitization, endocytosis and recycling are important for tolerance. Some of the 
assumptions underpinning explanations of how this works are incomplete or incorrect.  
Firstly βarr-2 binding and endocytosis are not necessary to produce desensitization of 
MOR. In the absence of βarr-2, other, non-arrestin mechanisms can very efficiently 
desensitize the receptor.  More importantly, there is now very strong evidence that one of 
the simplest explanations for greater tolerance with weakly-internalizing agonists, that 
phosphorylated and desensitized MOR accumulates at the surface because endocytosis is 
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required for dephosphorylation and resensitization, is incorrect. MOR dephosphorylates 
and resensitizes as efficiently or more efficiently when endocytosis is blocked, regardless 
of the agonist used. These findings are outlined in Figure 2. This demands rethinking of 
models used to explain the effects of transgenics and knockouts.  
 
The finding that rapid desensitization of MOR is enhanced and resensitization is 
impaired in locus coeruleus neurons after chronic morphine, if widely substantiated in 
other neurons, may contribute to further developments. If it is confirmed widely through 
the CNS and in different cellular compartments that enhanced rapid MOR desensitization 
and arrestin-dependent impairment of resensitization strongly contribute to opioid 
tolerance, then drugs able to elude these mechanisms might be found to produce less 
tolerance. The finding that a salvinorin A analogue, herkinorin, efficaciously engages 
MOR-G-protein signaling  but does not induce βarr-2 translocation, even when GRK2 is 
overexpressed (Groer et al., 2007), confirms the possibility that opioid agonists may be 
found that would not facilitate arrestin-dependent impairment of resensitization in 
tolerance. Virk et al. (2009) reported the intriguing finding that met-enkephalin can 
engage G-protein signaling in the presence of low concentrations of buprenorphine (a low 
efficacy for G-proteins, non-internalizing agonist) but no longer produces any rapid 
desensitization. If validated more widely this suggests that opioids, or related drugs could 
be found to stabilize MOR in conformations that are able to signal to G-proteins but 
cannot desensitize, which could perhaps limit tolerance. 
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Figure 1.  
 
Previous models to explain how strongly-internalizing opioid agonists can proiduc less 
tolerance than weakly-internalizing agonists. A Strongly-internalizing agonists induce 
rapid desenisitization of MOR-coupling. GRK2 mediated phosphorylation is pivotal for 
βarr-2 binding and endocytosis, both process that were considered ireversible at the cell 
surface, so MOR slowly resensitizes over the time course of endocytosis and recycling. B 
With weakly-internalizing agonists, MOR desensitizes slowly (accelerated by PKC 
activity) but accumulates in a phosphorylated desensitized state at the cell surface 
because it stimulates GRK2 and βarr-2 binding very weakly, so cannot resensitize 
causing tolerance.  As discussed in the text the crucial assumption that endocytosis (and 
recycling) is necessary for resensitization is incorrect. 
 
 
Figure 2.  
 
Summary of current evidence for mechanisms of MOR regulation in resensitization and 
tolerance.  A Desensitized MOR efficiently resensitizes when GRK2, βarr-2 (k.o.) or 
dynamin (to block endocytosis directly) are blocked suggesting that resensitization is 
very efficient in the absence of endocytosis. Directly blocking endocytosis with 
concanavalin A (ConA) does not affect resensitization or dephosphorylation of MOR. B 
After chronic morphine treatment desensitization is enhanced and resensitization is 
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blocked. This does not appear to involve changes in endocytosis but impaired 
resensitization is  restored to control rates by inhibiting GRK2, βarr-2 or dynamin.  
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